Share page on LinkedIn

Rare and orphan diseases

Unique challenges and complexities of rare and orphan disease clinical trials explored.

Beyond buzzwords: DE&I in rare disease

Beyond buzzwords: DE&I in rare disease

In an interdisciplinary panel discussion of research leaders and community advocates, we led a conversation on key challenges in advancing diversity, equity and inclusion and equitable access to rare disease clinical trials.

View panel discussion
Natural history studies to improve drug development in rare diseases

Natural history studies to improve drug development in rare diseases

Rare disease drug development is challenging due to limited info on patient distribution, change in disease progression and relevant outcomes to define treatment benefits.

Read the whitepaper
Unlocking the potential of advanced therapies developed for rare diseases

Unlocking the potential of advanced therapies developed for rare diseases

Development of advanced therapies for rare diseases requires a customised regulatory strategy. Discover an approach and interaction plan that sponsors can follow across all phases of development to accelerate time to market.

Read the whitepaper
ICON Supports World Rare Disease Day

ICON supports World Rare Disease Day

ICON is joining other healthcare & patient organisations to raise awareness of rare diseases on World Rare Disease Day.

Download the infographic
Participant-focused tools designed to improve study success in rare disease clinical trials

Participant-focused tools designed to improve study success in rare disease clinical trials

There is a recognised a gap in the availability of structured tools to help sponsors operationalise patient-centricity and identify and mitigate risks in rare disease clinical development.

Learn more
Read our whitepaper for insights on understanding the Bayesian and Frequentist approaches.

Leveraging historical data for use in rare disease trials

Rare disease clinical trials have several challenges that make them more difficult to conduct than clinical trials for more common diseases. Small patient populations, pediatric populations and the desire by patients and their caregivers to receive active therapy while on a clinical trial make it much more likely that these trials will need to incorporate historical data into the design.

Read the whitepaper
Patient centricity in orphan drug development

Patient centricity in orphan drug development

ICON analysed data on the use of patient-reported outcomes measures (PROMs) in orphan drug labeling claims and performed an extensive literature review on the use of PROMs in all phases of clinical research, observational/registry studies, and instrument development and validation. The findings and recommendations can be found in this whitepaper.

Read the whitepaper

Rare & Orphan Diseases media contributions

Receive more insights on rare and orphan diseases from ICON

Please visit ICON's Preference Centre and select 'rare diseases' under 'Therapeutic Areas of Interest' to receive new insights on rare and orphans diseases.

Receive new insights

Rare and orphan diseases videos

Rare and orphan diseases services

ICON is an experienced partner who can assist sponsors in navigating the many challenges of orphan drug development. ICON can help sponsors optimise the whole continuum of the clinical trial lifecycle from patient enrolment to payer reimbursement with its powerful solutions and proven strategies. ICON’s highly experienced clinical and therapeutic teams have conducted numerous rare disease trials across a wide range of therapeutic areas.

Read more about ICON's services in rare diseases